Spironolactone is a diuretic drug with a second life
In the wake of the unexpected success of cardiovascular (CV) outcome trials of several sodium glucose cotransporter type 2 (SGLT2) inhibitors and glucogonlike peptide 1 (GLP-1) receptor agonists, the approach to pharmacologic treatment of T2D has undergone a paradigm shift to prioritize agents that offer benefits beyond glycemic control
While methacrylates are well-known contact sensitizers, cyanoacrylates have caused only few cases of contact allergy
Future studies should prioritize (1) isolating and characterizing the active compounds within these botanicals, (2) elucidating their precise molecular targets (e.g., thyroid peroxidase, sodium-iodide symporter, cytokine signaling pathways), and (3) conducting well-designed controlled clinical trials to rigorously evaluate their safety and efficacy in human patients
These are studies of repair, recovery, and resilience